Depletion of DNA damage binding protein 2 sensitizes triple‐negative breast cancer cells to poly ADP‐ribose polymerase inhibition by destabilizing Rad51
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Depletion of DNA damage binding protein 2 sensitizes triple‐negative breast cancer cells to poly ADP‐ribose polymerase inhibition by destabilizing Rad51
Authors
Keywords
-
Journal
CANCER SCIENCE
Volume 110, Issue 11, Pages 3543-3552
Publisher
Wiley
Online
2019-09-22
DOI
10.1111/cas.14201
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Update on PARP Inhibitors in Breast Cancer
- (2018) Alexandra S. Zimmer et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- β1-Integrin Impacts Rad51 Stability and DNA Double-Strand Break Repair by Homologous Recombination
- (2018) Kazi Mokim Ahmed et al. MOLECULAR AND CELLULAR BIOLOGY
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling
- (2016) Chenghao Peng et al. CANCER RESEARCH
- A phosphorylation–deubiquitination cascade regulates the BRCA2–RAD51 axis in homologous recombination
- (2016) Kuntian Luo et al. GENES & DEVELOPMENT
- DDB2 increases radioresistance of NSCLC cells by enhancing DNA damage responses
- (2016) Ning Zou et al. TUMOR BIOLOGY
- Promotion of RAD51-Mediated Homologous DNA Pairing by the RAD51AP1-UAF1 Complex
- (2016) Fengshan Liang et al. Cell Reports
- FBH1 influences DNA replication fork stability and homologous recombination through ubiquitylation of RAD51
- (2015) Wai Kit Chu et al. Nature Communications
- New Strategies for Triple-Negative Breast Cancer--Deciphering the Heterogeneity
- (2014) I. A. Mayer et al. CLINICAL CANCER RESEARCH
- Multiple Regulation of Rad51-Mediated Homologous Recombination by Fission Yeast Fbh1
- (2014) Yasuhiro Tsutsui et al. PLoS Genetics
- DDB2: A Novel Regulator of NF- B and Breast Tumor Invasion
- (2013) M. Ennen et al. CANCER RESEARCH
- DDB2 Suppresses Epithelial-to-Mesenchymal Transition in Colon Cancer
- (2013) N. Roy et al. CANCER RESEARCH
- DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells
- (2013) Ran Zhao et al. MOLECULAR CANCER RESEARCH
- Investigation of Radiation-induced Transcriptome Profile of Radioresistant Non-small Cell Lung Cancer A549 Cells Using RNA-seq
- (2013) Hee Jung Yang et al. PLoS One
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
- (2012) X. Luo et al. GENES & DEVELOPMENT
- The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway
- (2010) Michael R. Lieber Annual Review of Biochemistry
- Tumor Growth Inhibition by Olaparib in BRCA2 Germline-Mutated Patient-Derived Ovarian Cancer Tissue Xenografts
- (2010) U. Kortmann et al. CLINICAL CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- A Postincision-Deficient TFIIH Causes Replication Fork Breakage and Uncovers Alternative Rad51- or Pol32-Mediated Restart Mechanisms
- (2010) María Moriel-Carretero et al. MOLECULAR CELL
- Overexpression of DDB2 enhances the sensitivity of human ovarian cancer cells to cisplatin by augmenting cellular apoptosis
- (2009) Bassant M. Barakat et al. INTERNATIONAL JOURNAL OF CANCER
- DDB2 decides cell fate following DNA damage
- (2009) T. Stoyanova et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- SUMO Modification Regulates BLM and RAD51 Interaction at Damaged Replication Forks
- (2009) Karen J. Ouyang et al. PLOS BIOLOGY
- Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin
- (2008) B. Evers et al. CLINICAL CANCER RESEARCH
- 4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
- (2008) Keith A. Menear et al. JOURNAL OF MEDICINAL CHEMISTRY
- Damaged DNA Binding Protein 2 Plays a Role in Breast Cancer Cell Growth
- (2008) Zilal Kattan et al. PLoS One
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now